

1 **Affinity tag coating enables reliable detection of antigen-specific**

2 **B cells in ImmunoSpot assays**

3  
4 Sebastian Köppert <sup>1,3</sup>, Carla Wolf <sup>1,3</sup>, Noémi Becza <sup>1</sup>, Giuseppe A. Sautto <sup>2</sup>, Fridolin Franke <sup>1</sup>,

5 Stefanie Kürten <sup>3</sup>, Ted M. Ross <sup>2,4</sup>, Paul V. Lehmann <sup>1</sup> and Greg A. Kirchenbaum<sup>1,\*</sup>

6  
7 <sup>1</sup>Research & Development Department, Cellular Technology Limited, Shaker Heights, OH

8 44122, USA; <sup>2</sup>Center for Vaccines and Immunology, University of Georgia, Athens, Georgia,

9 USA; <sup>3</sup>Institute of Anatomy and Cell Biology, Friedrich-Alexander University Erlangen-

10 Nürnberg; <sup>4</sup>Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.

11  
12 #Corresponding author: Greg A. Kirchenbaum, Ph.D., [greg.kirchenbaum@immunospot.com](mailto:greg.kirchenbaum@immunospot.com)

13

14 **ABSTRACT**

15           Assessment of humoral immunity to SARS-CoV-2 and other infectious agents is  
16 typically restricted to detecting antigen-specific antibody in the serum. Rarely does immune  
17 monitoring entail assessment of the memory B cell compartment itself, although it is these cells  
18 that engage in secondary antibody responses capable of mediating immune protection when pre-  
19 existing antibodies fail to prevent re-infection. There are few techniques that are capable of  
20 detecting rare antigen-specific B cells while also providing information regarding their  
21 precursory frequency, class/subclass usage and functional affinity. In theory, the  
22 ELISPOT/FluoroSpot (collectively ImmunoSpot) assay platform is ideally-suited for antigen-  
23 specific B cell assessments since it provides this information at single-cell resolution for  
24 individual antibody-secreting cells (ASC). Here, we tested the hypothesis that antigen coating  
25 efficiency could be universally improved across a diverse set of viral antigens if the standard  
26 direct (non-specific, low affinity) antigen absorption to the membrane was substituted by high  
27 affinity capture. Specifically, we report an enhancement in assay sensitivity and a reduction in  
28 required protein concentrations through the capture of recombinant proteins via their encoded  
29 hexahistidine (6XHis) affinity tag. Affinity tag antigen coating enabled detection of SARS-CoV-  
30 2 Spike receptor binding domain (RBD)-reactive ASC, and also significantly improved assay  
31 performance using additional control antigens. Collectively, establishment of a universal antigen  
32 coating approach streamlines characterization of the memory B cell compartment after SARS-  
33 CoV-2 infection or COVID-19 vaccinations, and facilitates high-throughput immune monitoring  
34 efforts of large donor cohorts in general.

35

36                   **INTRODUCTION**

37                   A successful and durable adaptive immune response comprises both expansion of short-  
38 lived effectors and development of long-lived memory cells. Focusing on the humoral  
39 component, this entails differentiation of antigen-specific B cells into antibody-secreting cells  
40 (ASC), capable of producing large quantities of affinity-matured immunoglobulin/antibody and  
41 expansion of antigen-experienced, class-switched memory B cells poised to rapidly respond  
42 upon future antigen encounter. Thus, to truly appreciate the scope of a given B cell response,  
43 both antigen-specific ASC and the memory cells themselves merit detailed study.

44                   Traditionally, monitoring of B cell responses has largely relied upon serum antibody  
45 measurements due to the ease of sample acquisition and high concentration of antibody in this  
46 biological fluid. However, secreted antibody exhibits a relatively short half-life (~3 weeks) *in*  
47 *vivo* [1, 2] and maintenance of serum antibody levels therefore requires continuous  
48 replenishment. With the exception of following acute antigen exposure, in which elevated  
49 frequencies of short-lived ASC can be found in circulation and transiently alter serum antibody  
50 reactivity [3-5], long-lived plasma cells (LLPC) residing in the bone marrow and secondary  
51 lymphoid tissues are chiefly responsible under steady state for the composition and specificity of  
52 serum antibody (reviewed by [6]). LLPC are thought to originate from terminally differentiated  
53 B cells that participated in T cell-dependent germinal center reactions [7, 8]. Short-lived ASC are  
54 also generated during T cell-dependent immune responses, yet only a subset of these ASC  
55 acquire the appropriate gene expression program and successfully occupy the specialized niche  
56 required for long-term survival and maintenance of sustained antibody production (reviewed by  
57 [9-11]).

58           Such LLPC and their secreted antibody represent the first line of humoral defense against  
59 re-infection with pathogens such as seasonal influenza [12], Ebola [13], Dengue [14] and most  
60 recently the SARS-CoV-2 virus [15]. Moreover, pre-existing antibody also serves to counter  
61 reactivation and subsequent dissemination of latent viral infections such as Epstein-Barr virus  
62 (EBV) [16] and human cytomegalovirus (HCMV) [17, 18]. In this context, elevated levels of  
63 serum antibody reactivity serve as a reliable indicator of antigenic exposure. However, both the  
64 size and longevity of an antigen-specific LLPC compartment, along with the magnitude and  
65 maintenance of serum antibody titers, are highly variable and also may be pathogen dependent  
66 (reviewed by [9, 19]). Consequently, while some individuals are endowed with LLPC that  
67 maintain stable titers of antigen-specific Ig for decades, in other instances antibody titers  
68 eventually wane to below the limit required for protection [20, 21] as also appears to be the case  
69 after SARS-CoV-2 infection [15, 22, 23].

70           In such instances, when pre-existing antibody abundance declines to below protective  
71 levels, long-lived memory B cells generated during the primary immune response can serve as  
72 the second line of humoral defense (reviewed by [24, 25]). Poised to rapidly respond upon  
73 antigen re-encounter and undergo robust proliferation, owing to their increased precursory  
74 frequency and expression of class-switched, affinity-matured B cell receptors (BCR), the  
75 resulting progeny include both additional long-lived memory B cells that await future antigen  
76 encounters and ASC capable of acutely raising antibody titers to combat and limit dissemination  
77 of the offending pathogen (reviewed by [26]). Hence, immune monitoring of underlying memory  
78 B cell frequencies, and their endowed antigen-specificity, can provide invaluable insights into  
79 whether these cells are capable of conferring immunological protection upon recall.

80           The study of antigen-specific memory B cells is complicated by their low precursory  
81 frequency and because in the absence of recent antigen encounter these cells exist in a resting  
82 state and are indistinguishable from other resting B cells on the basis of surface phenotype  
83 (reviewed by [27]). Consequently, techniques that yield single-cell resolution and which leverage  
84 the specificity of the BCR expressed by individual B cells are best suited for this task (reviewed  
85 by [28]). A commonly utilized approach for the identification of human memory B cells relies on  
86 flow cytometry and is dependent on BCR-mediated capture of antigen probes. While technically  
87 complex, this strategy has been implemented successfully for the study of memory B cell  
88 reactivity against targets such as influenza hemagglutinin [29], HIV envelope [30] and most  
89 recently the SARS-CoV-2 spike and nucleocapsid proteins [23, 31, 32]. Moreover, this  
90 methodology is conducive to multiplexing since several antigenic probes can be used in parallel  
91 with minimal interference [33]. In concert with advancements in the fields of flow cytometry,  
92 single-cell sequencing and bioinformatics, antigen probe-based memory B cell assessments offer  
93 an unprecedented window of detail into an individual's memory B cell composition (reviewed by  
94 [34]). Nevertheless, these data exist at the level of nucleotides and our present ability to translate  
95 these paired *IgH/IgL* sequences into predicted antigen binding *in silico* is still limited [35].  
96 Furthermore, despite optimizations improving the scalability of molecular cloning and  
97 expression of recombinant monoclonal antibodies (mAbs) obtained through antigen probe-based  
98 sequencing efforts, the characterization of individual mAbs isolated from multiple donors is  
99 costly, labor-intensive and not sufficiently throughput for its practical application in any sizeable  
100 immune monitoring effort.

101           As noted previously, memory B cells exist in a quiescent state in the absence of recent  
102 antigen encounter and importantly do not secrete their individual BCR as soluble antibody. To

103 overcome this obstacle, several *in vitro* stimulation protocols have been described that facilitate  
104 efficient antigen-independent differentiation of resting memory B cells into ASC [36-42]. In  
105 doing so, these *in vitro* stimulation protocols provide an alternative strategy for measurement of  
106 pre-existing memory B cells on the basis of their secreted antibody reactivity. First described by  
107 Czerkinsky [43], the traditional enzyme-linked immunospot (ELISPOT) assay technique enabled  
108 enumeration of individual ASC through the capture of their secreted Ig in close proximity to the  
109 secreting cell, and culminates with deposition of a precipitating substrate to reveal the individual  
110 antibody secretory foot-print. Owing to its plate-based format, relatively straight-forward  
111 procedural methodology and software-assisted counting algorithms, the ELISPOT technique is  
112 ideally-suited for large-scale assessments of ASC [44, 45]. In agreement, the B cell ELISPOT  
113 technique has successfully been implemented for the measurement of antigen-specific ASC  
114 against an array of both foreign [3, 4, 46-51] and self-antigens [52-54], and is a common  
115 approach for assessing B cell responses in the context of seasonal influenza vaccination where  
116 the complexities of pre-existing serum antibody reactivity exist [55, 56].

117         Subsequent adaptations of the ELISPOT method and usage of detection reagents coupled  
118 to fluorochromes with unique excitation and emission spectra is referred to as FluoroSpot.  
119 Assessment of B cell responses are particularly well-suited for the FluoroSpot platform because  
120 multiple Ig classes or IgG subclasses can be independently measured in parallel with no  
121 ambiguity or interference through usage of reagents conjugated with distinct fluorophores [57,  
122 58].

123         Using either an ELISPOT or FluoroSpot assay approach (collectively ImmunoSpot), or if  
124 a single or multiple antibody class/subclass are measured, the greatest obstacle to detection and  
125 subsequent successful enumeration of antigen-specific ASC is achieving a sufficiently high

126 density of antigen coating on the membrane of the assay well itself. Unlike in a B cell  
127 ImmunoSpot assay measuring total ASC, in which the secreted antibody is captured with fixed  
128 affinity through capture by polyclonal reagents recognizing multiple epitopes in the constant  
129 region of the kappa and lambda light chains, respectively, in an antigen-specific application the  
130 efficiency of antibody/antigen binding and its ultimate retention in close proximity to the  
131 secreting cells is intrinsically tied to an individual ASC's fine specificity. In this regard, inherent  
132 differences in ASC affinity for the nominal antigen could account for diversity in ImmunoSpot  
133 morphologies [59]. Supporting this notion, and in agreement with the polyclonal nature and  
134 diversity of BCR affinities present in a given B cell repertoire, a spectrum of antigen-specific  
135 spot sizes are commonly observed in ImmunoSpot assays [36, 60-62]. By extension, the capacity  
136 to detect antigen-specific ASC spanning a broad spectrum of affinity, along with the sensitivity  
137 to reliably detect ASC with reduced functional affinity, using either the ELISPOT or FluoroSpot  
138 assay platform is intimately associated with the antigen coating component since it is responsible  
139 for capture and retention of secreted Ig in close proximity to the secreting cell.

140         Microplates with polyvinylidene difluoride (PVDF) membranes are considered the gold  
141 standard for usage in ImmunoSpot assays due to their porosity and ability to bind high  
142 concentrations of antibodies [63, 64]. However, PVDF membranes are intrinsically hydrophobic  
143 and absorption of biomolecules is mediated primarily through hydrophobic and dipole  
144 interactions. Consequently, establishment of antigen-specific B cell ImmunoSpot assays is often  
145 limited by the unique biochemistry of the coating antigen itself, that is, whether it can be  
146 efficiently absorbed to the membrane. While increasing the concentration of some coating  
147 antigens can improve the quantity of protein absorbed to the membrane, this may be prohibitive  
148 due to the associated cost or abundance of antigen required. Lastly, due to their hydrophilic

149 nature, there are antigens that cannot be effectively coated to PVDF membranes even at  
150 excessively high concentrations.

151 In this communication, we describe a universal antigen coating approach for efficient  
152 absorption of recombinantly-expressed antigens representing a diverse set of viral pathogens  
153 through exploiting their genetically-encoded hexahistidine (6XHis) affinity tags. Using murine B  
154 cell hybridomas and primary human memory B cells secreting antibody specificities spanning a  
155 spectrum of affinity as model ASC, we highlight improvements in the sensitivity of antigen-  
156 specific B cell FluoroSpot assays, especially in the context of ASC with reduced functional  
157 affinity. When combined with the beneficial attributes of the FluoroSpot detection platform, the  
158 optimizations in antigen coating reported herein open the door to larger-scale immune  
159 monitoring efforts of underlying memory B cell reactivity using diverse panels of antigens, along  
160 with more sophisticated image analysis approaches that appreciate the attributes of individual  
161 ASC.

## 162 **MATERIALS AND METHODS**

### 163 *Human subjects*

164 Peripheral blood mononuclear cells (PBMC) of human subjects tested in this study were  
165 obtained from healthy adults and originate from ePBMC® library (Cellular Technology Limited  
166 (CTL), Shaker Heights, OH, USA). These subjects were recruited by Hemacare (Van Nuys, CA,  
167 USA) or American Red Cross (Atlanta, GA, USA) with IRB approvals and were sold to CTL  
168 identifying donors by code only while concealing the subjects' identities. The PBMC were then  
169 cryopreserved and stored in liquid nitrogen until testing.

### 170 *Polyclonal human B cell stimulation*



171 Thawing, washing and counting of PBMC was performed according to previously  
172 described protocols [65, 66] using CTL's Live/Dead cell counting suite on an ImmunoSpot® S6  
173 Ultimate Analyzer (CTL). Subsequently, cells were resuspended at  $2 \times 10^6$  cells/mL in complete  
174 B cell medium (BCM) containing RPMI 1640 (Lonza, Walkersville, MD) supplemented with 10%  
175 fetal bovine serum (Gemini Bioproducts, West Sacramento, CA, USA), 100U/mL penicillin,  
176 100µg/mL streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, 8mM HEPES (all obtained  
177 from Life Technologies, Grand Island, NY, USA) and 50µM beta-mercaptoethanol (Sigma-  
178 Aldrich, St. Louis, MO, USA) containing B-Poly-S™ reagent (from CTL). Cells were then  
179 transferred into tissue culture flasks (Corning, Sigma-Aldrich) and incubated at 37°C, 5% CO<sub>2</sub> for  
180 five days prior to usage in B cell ImmunoSpot® assays. Following polyclonal stimulation, cells  
181 were washed with PBS and then resuspended in complete BCM at  $1-3 \times 10^6$  live cells/mL (antigen-  
182 specific) or  $3 \times 10^5$  live cells/mL (total) and used immediately in ImmunoSpot® assays.

183

#### 184 *Recombinant proteins*

185 Recombinant hemagglutinin (rHA) proteins encoding A/California/04/2009 (CA/09,  
186 H1N1) or A/Texas/50/2012 (TX/12, H3N2) vaccine strains were acquired from the Center for  
187 Vaccines and Immunology (CVI) (University of Georgia, Athens, GA, USA) and have been  
188 described previously [67]. Additionally, full-length SARS-CoV-2 Spike protein [68], along with  
189 a truncated version representing the receptor binding domain (RBD) [69], was also generously  
190 provided by CVI at UGA. Recombinant Epstein-Barr virus (EBV) nuclear antigen (EBNA1)  
191 protein was purchased from Serion (Würzburg, Germany). Cytomegalovirus gH pentamer  
192 complex was purchased from The Native Antigen Company (Oxford, UK). SARS-CoV-2 Spike  
193 (S1 fragment) was purchased from Creative Diagnostics (Shirley, NY, USA). Importantly, all

194 recombinant proteins used in this study possessed a genetically-encoded hexahistidine (6XHis)  
195 affinity tag.

196

#### 197 *Total (IgA/IgG/IgM) Human B cell ImmunoSpot® assays*

198 For enumeration of antibody-secreting cells (ASC), irrespective of their antigen specificity,  
199 cell suspensions were serially diluted 2-fold in duplicates, starting at  $3 \times 10^4$  live cells/well, in  
200 round-bottom 96-well tissue culture plates (Corning, Sigma-Aldrich) and subsequently transferred  
201 into assay plates precoated with anti-Ig $\kappa$ / $\lambda$  capture antibody contained in the human IgA/IgG/IgM  
202 Three-Color ImmunoSpot® kit (from CTL). Plates were incubated for 16hr at 37°C, 5% CO<sub>2</sub>, and  
203 plate-bound Ig spot-forming units (SFU), each representing a secretory footprint of an individual  
204 ASC, were revealed using the IgA-, IgG- and IgM-specific detection reagents contained in the kit,  
205 which was used according to the manufacturer's instructions.

206

#### 207 *Antigen-specific Human B cell ImmunoSpot® assays*

208 For enumeration of antigen-specific ASC, 6XHis-tagged protein antigens were coated  
209 directly into 70% (v/v) EtOH pre-conditioned assay wells at 10 $\mu$ g/mL in PBS overnight at 4°C.  
210 Alternatively, 6XHis-tagged protein solutions at 10 $\mu$ g/mL in PBS (unless otherwise specified)  
211 were applied to EtOH pre-conditioned wells precoated overnight at 4°C with 10 $\mu$ g/mL (unless  
212 otherwise specified) anti-His tag antibody (Biolegend, San Diego, CA) and incubated overnight at  
213 4°C to improve antigen absorption. Following one wash with 150 $\mu$ L PBS, plates were blocked  
214 with 150 $\mu$ L complete BCM for 1h at room temperature prior to addition of polyclonally-stimulated  
215 PBMC (1-3  $\times 10^5$  cells/well). Plates were then incubated for 16hr at 37°C, 5% CO<sub>2</sub>, and SFU were

216 visualized using the human IgA/IgG/IgM Three-Color ImmunoSpot® kit (from CTL) according  
217 to the manufacturer's instructions.

218

### 219 *Murine B cell hybridomas*

220 Murine B cell hybridoma lines secreting (IgG1,  $\kappa$ ) monoclonal antibody (mAb) with  
221 reactivity against the hemagglutinin (HA) protein of the pandemic H1N1 (pH1N1)  
222 A/California/04/2009 (CA/09) influenza vaccine strain have been reported previously [70]. These  
223 B cell hybridoma lines were additionally single-cell subcloned upon receipt, and the selected  
224 subclone is denoted. Murine B cell hybridoma lines secreting mAb with reactivity against the  
225 Spike protein of SARS-CoV-2 were generated from DBA/2J mice (Jackson Laboratory, Bar  
226 Harbor, Maine, USA) that were immunized intraperitoneally with heat-inactivated SARS-CoV-2  
227 virus antigen [71] (~100 $\mu$ L of virus antigen/mouse) adjuvanted with alum hydroxide on day 0, day  
228 21 and day 42. To focus antibody reactivity towards the Spike protein, mice were boosted  
229 intraperitoneally with 15 $\mu$ g of SARS-CoV-2 Spike protein [68] adjuvanted with aluminum  
230 hydroxide on Day 63. Mice received a final intraperitoneal booster immunization with 15 $\mu$ g of  
231 full-length SARS-CoV-2 Spike protein in PBS on Day 77 and fusion of immune splenocytes with  
232 SP2/0 myeloma cells was performed four days later following similar methods as described  
233 previously [70, 72]. B cell hybridomas were then single-cell cloned using FACS, as previously  
234 described [70]. All B cell hybridoma lines were cultured in complete BCM at 37°C, 5% CO<sub>2</sub>.

235

### 236 *Murine B cell ImmunoSpot® assays*

237 Murine B cell hybridoma cells were washed with complete BCM to remove residual mAb in  
238 the solution prior to plating into ImmunoSpot® assays. For enumeration of total ASC, irrespective

239 of their antigen-specificity, ~100 B cell hybridomas were input into wells precoated with anti-Igκ  
240 capture antibody contained in mouse B cell ImmunoSpot® kits (from CTL). For enumeration of  
241 antigen-specific ASC, and comparison of FluoroSpot formation, murine B cell hybridomas were  
242 seeded into wells coated directly with CA/09 rHA or SARS-CoV-2 Spike protein at 10μg/mL or  
243 25μg/mL. Alternatively, CA/09 rHA or Spike proteins at 10μg/mL were applied to wells precoated  
244 with anti-His mAb (IgG2b, κ) (Thermo Fisher, Waltham, MA, USA) as detailed above. Following  
245 input of B cell hybridomas into assay wells, plates were incubated for 16hr at 37°C, 5% CO<sub>2</sub>, and  
246 SFU, each representing a secretory foot-print of an individual ASC, were visualized using the IgG1  
247 subclass-specific detection component of the mouse IgG1/IgG2a/IgG2b Three-Color  
248 ImmunoSpot® kit (from CTL) according to the manufacturer's instructions.

249

#### 250 *ImmunoSpot® image acquisition and counting*

251 Following completion of B cell ImmunoSpot® assay detection systems, plates were air-  
252 dried prior to scanning on an ImmunoSpot® S6 Ultimate Analyzer. SFU were then enumerated  
253 using the Basic Count mode of CTL ImmunoSpot SC Studio (Version 1.6.2). As ImmunoSpot®  
254 Multi-color B cell kits, analyzers and software proprietary to CTL were used in this study; we refer  
255 to this collective methodology as ImmunoSpot®.

256

#### 257 *Bivariate visualization of FluoroSpots*

258 Counted FluoroSpots from replicate wells of an individual B cell hybridoma line or donor  
259 and originating from the same coating condition (direct or affinity capture) were merged into flow  
260 cytometry standard (FCS) files using CTL ImmunoSpot SC Studio software and were  
261 subsequently visualized using Flowjo™ (Version 10.6.2) (Ashland, Oregon USA).

262

263 *Statistical Methods*

264 An analysis of variation (ANOVA) with Sidak's post-hoc test was used to identify  
265 differences in SFU/well between antigen-coating conditions. (GraphPad Prism 9, San Diego, CA,  
266 USA)

267

268 **RESULTS**

269 **Affinity tag capture of SARS-CoV-2 Spike protein improves antigen-specific FluoroSpot**  
270 **assays.**

271 We set out to develop a SARS-CoV-2 Spike-specific B cell ImmunoSpot assay to  
272 determine whether this assay format was suitable for immune monitoring of antigen-specific  
273 memory B cells following resolution of COVID-19. To monitor B cell reactivity against the SARS-  
274 CoV-2 Spike protein, we evaluated two candidate antigens representing the S1 component or the  
275 receptor binding domain (RBD). Both antigen targets have been used previously for evaluating  
276 prior infection with SARS-CoV-2 on the basis of serum antibody reactivity [73, 74]. Additionally,  
277 serum antibody reactivity against the RBD protein is a strong predictor of neutralizing activity [74,  
278 75]. As shown in Figure 1A, direct capture of the RBD protein at 10 $\mu$ g/mL to the assay membrane  
279 failed to yield bright and well-defined IgG<sup>+</sup> FluoroSpots following overnight incubation of pre-  
280 stimulated PBMC from four recovered COVID-19 donors. By contrast, IgG<sup>+</sup> FluoroSpots  
281 generated in wells coated in parallel with the same RBD protein solution (at 10 $\mu$ g/mL) using the  
282 affinity capture approach exploiting the genetically encoded hexahistidine (6XHis) tag were  
283 readily apparent. Affinity capture of RBD protein not only yielded an increased number of antigen-  
284 specific IgG<sup>+</sup> FluoroSpots, but also led to an enhancement of their intensity and reduction in size

285 (collectively referred to as morphology) relative to FluoroSpots detected in wells in which RBD  
286 protein was directly captured. Importantly, IgG<sup>+</sup> FluoroSpots were not present in wells coated in  
287 parallel with the anti-6XHis capture mAb and 6XHis peptide (data not shown).

288 While all three improvements in B cell FluoroSpot assay performance and detection of  
289 individual ASC are readily perceived visually (increase in spot numbers, increase in spot intensity  
290 and improved size definition), they can also be graphically represented in bivariate plots using the  
291 flow cytometry standard (FCS) output of ImmunoSpot® data. In addition to increased SFU counts  
292 in the affinity capture compared to direct RBD coated wells (shown in red and black, respectively,  
293 in the upper right corner of each panel), an increase in FluoroSpot intensity and reduction of their  
294 size was also apparent by the shift to the right and down of the (red) spot clouds for each donor  
295 (Figure 1B). In this representation of the data, bright and pristine FluoroSpots will cluster towards  
296 the lower right quadrant of intensity vs size plots. In contrast, large and faint FluoroSpots that are  
297 barely countable will locate to the upper left quadrant of such bivariate plots. Importantly, as nearly  
298 all RBD-specific FluoroSpots detected in directly coated wells resided in the upper left quadrant,  
299 the affinity capture approach enabled unambiguous detection of memory B cells that were barely  
300 discernable using a standard antigen coating approach.

301 Additionally, we also evaluated these same COVID-19 recovered donors for evidence of  
302 antigen-specific B cell memory targeting the S1 component of the SARS-CoV-2 Spike protein.  
303 Whereas direct capture of S1 protein yielded detectable IgG<sup>+</sup> FluoroSpots and evidence of  
304 immunological memory, these FluoroSpots were faint and diffuse (Figure 2A). In comparison,  
305 FluoroSpots generated in wells in which the S1 protein was affinity captured via its 6XHis tag  
306 appeared more intense and well-defined. Consistent with the RBD data, we also detected a greater

307 abundance of S1-specific IgG<sup>+</sup> FluoroSpots in wells coated through affinity capture and these  
308 FluoroSpots exhibited an enhanced morphology (Figure 2B).

309         Lastly, to more precisely define the improvement realized through testing primary human  
310 B cells in affinity captured versus vs directly antigen coated assay wells, we leveraged a panel of  
311 four murine B cell hybridoma lines capable of secreting mAb with specificity for the full-length  
312 SARS-CoV-2 Spike protein. Unlike in the context of B cell immune monitoring efforts, in which  
313 the response is polyclonal and the B cell repertoire involved spans a spectrum of functional  
314 affinities for the antigen, the usage of B cell hybridomas as model ASC enabled direct comparison  
315 of protein coating efficiency in the context of ImmunoSpot assays since these lines secrete  
316 monoclonal antibody (mAb) with defined specificity and epitope recognition for the Spike protein.  
317 As shown in Figure 3A, each of these B cell hybridoma lines yielded clearly-defined FluoroSpots  
318 when the assay well was coated with antibody specific for the Igk light chain, that is, when secreted  
319 immunoglobulin was detected irrespective of its antigen specificity. Counterstaining with IgG  
320 subclass-specific detection antibodies established that all four hybridomas secreted an IgG1,  $\kappa$   
321 mAb. Next, we evaluated the capacity of these B cell hybridoma lines to generate antigen-specific  
322 FluoroSpots in wells in which the Spike protein was directly captured at 25 $\mu$ g/mL or 10 $\mu$ g/mL, or  
323 in wells coated at 10 $\mu$ g/mL using the affinity capture approach. All four B cell hybridoma lines  
324 were capable of antigen-specific FluoroSpot formation in wells coated directly with 25 $\mu$ g/mL of  
325 the Spike protein. However, 3 of 4 B cell hybridoma lines exhibited a significant reduction in spot-  
326 forming units (SFU) when seeded into wells coated directly with 10 $\mu$ g/mL of Spike protein (Figure  
327 3B). Importantly, the affinity capture of Spike protein yielded a significant improvement in the  
328 abundance of detectable FluoroSpots for the same three B cell hybridoma lines. Furthermore, the  
329 FluoroSpot morphology was greatly enhanced for each of these model ASC when Spike protein

330 was affinity captured (Figure 3C). Collectively, these data suggest that each of the 6XHis-tagged  
331 recombinant Spike antigen probes evaluated for utility in B cell ImmunoSpot assays were more  
332 efficiently coated using an affinity capture approach compared to direct capture of these antigens  
333 to the assay membrane itself.

334

335 **Affinity tag capture of EBV EBNA1 protein improves detection of antigen-specific memory**  
336 **B cells.**

337 Encouraged by the improvements in detection of SARS-CoV-2 Spike-specific IgG<sup>+</sup> ASC  
338 afforded through the affinity capture of 6XHis-tagged antigens, we next sought to establish B cell  
339 ImmunoSpot assays for other viral antigens that could serve as specificity controls while  
340 monitoring for B cell memory against SARS-CoV-2. As one such candidate virus, we attempted  
341 to detect pre-existing human memory B cell reactivity against Epstein-Barr virus (EBV).  
342 Successful detection of memory B cell reactivity against EBV is relevant in the context of immune  
343 monitoring since this herpesvirus causes infectious mononucleosis and is also linked to several  
344 hematopoietic malignancies [76, 77]. Moreover, EBV can persist in a latent state within the  
345 memory B cell compartment for the lifetime of a host [78]. Of particular interest, the Epstein-Barr  
346 nuclear antigen 1 (EBNA1) protein possesses multiple independent roles in viral latency (reviewed  
347 by [79]) and serum antibody reactivity to EBNA1 predominates during latent EBV infection [80].

348 Consistent with our observations using recombinant S1 protein, IgG<sup>+</sup> FluoroSpots could  
349 be detected in wells in which EBNA1 protein was directly captured on the assay membrane (Figure  
350 4A). However, in comparison, a greater number of EBNA1-specific IgG<sup>+</sup> FluoroSpots were  
351 detected in wells coated using an affinity capture approach. Furthermore, the observed FluoroSpots  
352 in the affinity captured antigen coated wells possessed a greater fluorescence intensity and were



353 larger in size compared to FluoroSpots detected in wells in which the EBNA1 protein was directly  
354 captured (Figure 4B). Therefore, affinity capture of EBNA1 protein improved detection of antigen-  
355 specific human ASC by all three criteria: spot number, spot intensity and spot size definition.

356

357 **Affinity tag capture of HCMV gH protein improves detection of antigen-specific memory B**  
358 **cells.**

359 As a second control antigen system for monitoring SARS-CoV-2-specific B cells, we also  
360 evaluated the efficiency of detecting memory B cell reactivity against human cytomegalovirus  
361 (HCMV). In the context of immune monitoring of underlying memory B cell reactivity against  
362 HCMV, we utilized a recombinant gH pentamer complex as our coating antigen since it is a known  
363 target of neutralizing antibodies [81]. As shown in Figure 5A, direct capture of the gH pentamer  
364 complex protein at 10 $\mu$ g/mL failed to yield well-defined IgG<sup>+</sup> FluoroSpots. Instead, the observed  
365 FluoroSpots were weakly fluorescent and diffuse, and barely countable. In support of the  
366 improvement in antigen coating afforded through affinity capture of the 6XHis-tagged gH  
367 pentamer complex, both an increase in the number of IgG<sup>+</sup> FluoroSpots detected and enhancement  
368 of their fluorescence intensity was observed. Nevertheless, despite superior detection of gH-  
369 specific IgG<sup>+</sup> ASC using the affinity capture coating approach, these FluoroSpots were still at the  
370 threshold of reliable detection. Therefore, we evaluated the hypothesis that increasing the quantity  
371 of both the anti-6XHis capture mAb and gH pentamer complex used for affinity capture coating  
372 would further improve the detection of gH-specific IgG<sup>+</sup> ASC and enhance the intensity of the  
373 resulting FluoroSpots. As shown in Figure S1, and supporting our hypothesis, a significant  
374 increase in the number of gH-specific IgG<sup>+</sup> ASC was detected in wells coated with 20 $\mu$ g/mL of  
375 gH complex using an affinity capture approach. Furthermore, the FluoroSpots in these wells

376 exhibited an improved morphology on the basis of fluorescence intensity and size. Collectively,  
377 these data highlight the improvement in assay sensitivity afforded through affinity capture of  
378 recombinant proteins via their encoded 6XHis affinity tag.

379

### 380 **Affinity tag capture of influenza hemagglutinin improves antigen-specific FluoroSpot assays.**

381 As additional controls for monitoring SARS-CoV-2-specific B cell memory, we also  
382 sought to evaluate the efficiency of detecting memory B cell reactivity against recombinant  
383 hemagglutinin (rHA) proteins representing prototype H1N1 (A/California/04/2009, CA/09) and  
384 H3N2 (A/Texas/50/2012) influenza vaccine strains. Direct capture of CA/09 rHA protein at  
385 10 $\mu$ g/mL yielded well-defined IgG<sup>+</sup> FluoroSpots for each of the four donors evaluated (Figure  
386 6A). Additionally, affinity capture of CA/09 rHA did not further increase the number of detectable  
387 antigen-specific IgG<sup>+</sup> FluoroSpots. However, affinity capture of CA/09 rHA did increase the  
388 fluorescence intensity and size of the observed FluoroSpots (Figure 6B). In contrast, affinity  
389 capture of TX/12 rHA protein afforded a clear improvement in the number of antigen-specific  
390 IgG<sup>+</sup> ASC detected (Figure S2). Moreover, both the intensity and size of the observed antigen-  
391 specific IgG<sup>+</sup> FluoroSpots were augmented in wells coated with TX/12 rHA through affinity  
392 capture.

393 To reconcile the discrepancy between the improvement in antigen coating observed in the  
394 context of TX/12 rHA with the observation that affinity capture of CA/09 rHA afforded only a  
395 modest benefit, we next evaluated the formation of CA/09 rHA-specific FluoroSpots using murine  
396 B cell hybridomas as ASC. As noted previously, usage of B cell hybridomas as ASC is an ideal  
397 approach to directly evaluate any improvements in protein coating efficiency in the context of  
398 ImmunoSpot assays since these cells secrete monoclonal antibody (mAb) with defined specificity

399 and epitope recognition for the CA/09 rHA protein. Moreover, the affinity of the secreted mAb is  
400 fixed and enables assessment of B cell hybridoma lines known to secrete mAb with varying  
401 functional affinities. As shown in Figure 7A, each of the four selected murine B cell hybridoma  
402 lines yielded well-defined FluoroSpots when their secreted antibody was captured irrespective of  
403 its antigen-specificity, and each was confirmed to secrete IgG1,  $\kappa$ . Three of these B cell hybridoma  
404 lines were capable of generating well-defined CA/09 rHA-specific FluoroSpots when the protein  
405 was directly captured at 25 $\mu$ g/mL. The fourth B cell hybridoma line (4-G10.3) yielded only faint  
406 FluoroSpots in these directly coated wells, indicating a failure of the secreted mAb to be retained  
407 in close proximity to the secreting cell as a consequence of poor binding. Of the three lines that  
408 yielded definitive FluoroSpot formation in wells coated with 25 $\mu$ g/mL of CA/09 rHA, two  
409 demonstrated a significant reduction in SFU in wells in which CA/09 rHA was directly captured  
410 at 10 $\mu$ g/mL (Figure 7B). Importantly, affinity capture of CA/09 rHA at 10 $\mu$ g/mL significantly  
411 improved FluoroSpot formation for both of these lines, and greatly enhanced FluoroSpot  
412 morphology (Figure 7C). Collectively, the data generated using the CA/09 rHA and TX/12 rHA  
413 proteins further support the notion that affinity capture of 6XHis-tagged proteins offers a robust  
414 strategy for achieving optimal antigen coating and reliable detection of antigen-specific ASC using  
415 the ImmunoSpot platform and permits detection of ASC that produce antibodies of reduced  
416 functional affinity for an antigen of interest.

417

## 418 DISCUSSION

419 Using an affinity capture coating approach leveraging the genetically encoded  
420 hexahistidine (6XHis) affinity tag commonly expressed by recombinant proteins, we introduce a  
421 universal platform for antigen absorption that improved the sensitivity of B cell ImmunoSpot

422 assays. Using murine B cell hybridomas and *in vitro* differentiated human memory B cells as  
423 model ASC, we demonstrate the utility of the affinity capture approach across a variety of  
424 recombinant proteins: seasonal influenza (H1N1 and H3N2), latent herpesviruses (EBV and  
425 HCMV) and most notably the pandemic SARS-CoV-2 virus. Beyond reducing the concentration  
426 required to achieve efficient protein coating, as evidenced by increased antigen-specific SFU, the  
427 affinity capture approach also enhanced assay sensitivity based on augmented FluoroSpot  
428 intensity and size. Collectively, these data highlight the suitability of the FluoroSpot assay  
429 platform for high-throughput and systematic assessment of underlying memory B cell reactivity,  
430 or *in vivo* differentiated ASC such as plasmablasts or LLPC, against diverse panels of  
431 recombinantly-expressed protein antigens. Our data show that affinity antigen coating was  
432 critical for developing high resolution B cell ImmunoSpot assays for SARS-CoV-2, including  
433 control antigens, and suggest that this approach may facilitate B cell immune monitoring in  
434 general.

435       Exploitation of the 6XHis affinity tag for capture and subsequent purification of  
436 recombinant proteins is widely used [82]. Due to its small size, polyhistidine affinity tags are  
437 easily incorporated into either the N- or C-terminus of expression vectors, or the nucleotide  
438 sequence of the recombinant protein itself using polymerase chain reaction, and rarely does  
439 inclusion of this affinity tag affect protein function or structural integrity. Moreover, there are a  
440 variety of commercially available cloning vectors for the generation and expression of His-  
441 tagged recombinant proteins in different expression systems. The 6XHis affinity tag is only one  
442 of several previously described for subsequent purification of recombinant proteins [83].  
443 Specifically, alternative affinity tags commonly used for purification of recombinant proteins  
444 include FLAG [84], HA [85], c-Myc [86] and Strep II [87]. In combination with the respective

445 companion anti-tag mAb, or using a modified Strep-Tactin protein that binds the Strep II tag  
446 with high-affinity, these affinity tags may also lend themselves to similar usage in the context of  
447 antigen-specific ImmunoSpot assays. In this regard, further investigation into the applicability of  
448 alternative anti-tag capture systems for improved antigen absorption in the ImmunoSpot platform  
449 are merited, but are beyond the scope of this communication.

450         Initially commercialized for filtration applications, the porosity and high antibody  
451 binding properties of polyvinylidene fluoride (PVDF) membranes render them ideally-suited for  
452 usage in ImmunoSpot applications [64]. According to general knowledge, proteins are absorbed  
453 on PVDF membranes through hydrophobic and dipole interactions. However, it stands to reason  
454 that usage of PVDF membranes may not be optimal for all B cell ImmunoSpot applications due  
455 to the unique biochemistry and diversity of macromolecules that constitute the antigenic  
456 universe. In this context, the affinity capture approach described in this communication  
457 circumvents the variability introduced through absorption of proteins on the basis of their unique  
458 conformation and amino acid sequence composition. Instead, a diversity of recombinant proteins  
459 bearing the 6XHis or an alternative affinity tag may be efficiently coated in a relatively straight-  
460 forward and streamlined fashion through preconditioning the assay well first with the  
461 corresponding high-affinity capture reagent followed by subsequent acquisition of soluble  
462 protein.

463         Conceptually, the affinity capture approach may improve assay sensitivity and reduce the  
464 concentration required to detect antigen-specific ASC by better preserving the tertiary (or  
465 quaternary) structure of coating antigens through directing their interaction with the capture  
466 surface to a defined foot-print. In this way, the chance that absorption of antigen directly to the  
467 PVDF membrane could result in protein distortion and subsequent destruction of relevant

468 epitopes would be reduced. Moreover, the affinity-tagged protein is likely to project away from  
469 the membrane and this could avoid steric hinderance and enhance accessibility of secreted  
470 antibody for certain epitopes. Another benefit of the affnity capture approach may be the ability  
471 to achieve a higher local density of antigen in close proximity to each other relative to that  
472 achieved when antigen is applied directly to the assay membrane. Since retention of the secreted  
473 antibody in close proximity to the source cell is essential for detection of antigen-specific  
474 ImmunoSpots, especially for ASC with reduced functional affinity, improvements in antigen  
475 spatial packing are in line with our observations of improved assay sensitivity. In support of this  
476 hypothesis, we observed distinct increases in the intensity of antigen-specific FluoroSpot in  
477 several donors and murine B cell hybridoma lines.

478         With the exception of the CA/09 rHA coating antigen, we present evidence for improved  
479 sensitivity in the detection of underlying human memory B cell reactivity against several viral  
480 pathogens using an affinity capture approach. This observation could suggest that the CA/09  
481 rHA protein, unlike the other recombinant proteins used as coating antigens for B cell  
482 FluoroSpot assays, was efficiently captured directly on the assay membrane. However, in light of  
483 the increased SFU and FluoroSpot intensity observed using CA/09 rHA-specific murine B cell  
484 hybridomas as model ASC (Figure 7), we consider this explanation unlikely. Alternatively, this  
485 result could merely be due to the limited number of donors that were evaluated in parallel (n=4)  
486 for FluoroSpot formation against the CA/09 rHA. Instead, we speculate that CA/09 rHA-specific  
487 ASC in these human donors were endowed with increased affinity. Supporting the hypothesis  
488 that CA/09 rHA-specific ASC possess increased affinity due to previous affinity maturation; the  
489 human population is routinely exposed to H1N1 viruses through natural infection or prophylactic  
490 vaccination [88]. Furthermore, the H1N1 component in the annual seasonal influenza vaccine

491 has been antigenically matched or was quite similar to the CA/09 rHA for the past decade. To  
492 this end, a more detailed assessment of CA/09 rHA-specific ASC and their resulting FluoroSpot  
493 morphologies using a larger donor cohort pool would resolve this open question, but was beyond  
494 the scope of this communication.

495 As an additional component of our antigen-specific FluoroSpot analysis pipeline, we  
496 leveraged the ImmunoSpot® counting software's capacity to export flow cytometry standard  
497 (FCS) files and subsequently segregated individual FluoroSpots on the basis of their intensity  
498 and size. Visualizing the FluoroSpot data in a bivariate plot representing these parameters, and  
499 overlaying the counted FluoroSpot events occurring in wells in which the antigen was directly or  
500 affinity captured, enabled a clear visualization of the qualitative changes afforded through  
501 affinity capture coating of the antigen. Through extension, and based on mathematical modeling,  
502 there should be a relationship between the size and intensity (collectively termed morphology) of  
503 antigen-specific FluoroSpots derived from ASC with differential affinity [59]. Improvements in  
504 antigen absorption in this context are thus invaluable since they conceptually extend the window  
505 of observation through enabling detection of FluoroSpots originating from ASC with reduced  
506 functional affinity and would offer insights into whether recall responses exhibit evidence of  
507 affinity maturation [89]. Nevertheless, due to the polyclonal nature and diversity of epitopes  
508 recognized by individual antigen-specific human ASC, experimental efforts intending to confirm  
509 and extend the association between antibody functional affinity and FluoroSpot morphology are  
510 best resolved using model ASC that span a defined range of affinity and recognize a common  
511 epitope (Becza *et al.*, manuscript in preparation). Furthermore, while an association between  
512 mAb functional affinity and FluoroSpot formation/morphology was not readily apparent using  
513 the limited number of CA/09 rHA- and SARS-CoV-2 Spike-specific B cell hybridoma lines

514 detailed in this communication, assessment of a larger collection of model ASC will be needed to  
515 lend support to this hypothesis.

516         The improvements in antigen coating described in this communication also serve to  
517 elevate the utility of the ImmunoSpot platform itself. Owing to its capacity to provide detailed  
518 information beyond the Ig class or IgG subclass usage of individual antigen-specific ASC, it also  
519 serves as a key methodology to bridge assessments of acute B cell responses. ImmunoSpot  
520 assays permit to detect plasmablasts directly *ex vivo* through their spontaneous antibody  
521 secretion. In contrast the memory B cell component, consisting of resting lymphocytes, can be  
522 detected via its ASC activity only following *in vitro* differentiation. Moreover, ongoing  
523 optimizations in cryopreservation of resting B cells and B cell blasts [66, 90], along with the  
524 high-throughput capability of the ImmunoSpot approach, also enable simultaneous assessments  
525 of these respective compartments and detailed comparisons; such as Ig class usage and relative  
526 precursory frequency. In this context, it is important to note that acutely following infection or  
527 vaccination, the majority of circulating plasmablasts will be endowed with high-affinity, antigen-  
528 specific BCR since they were successfully recruited into the T cell-dependent immune response  
529 [4, 91]. In stark contrast, ASC with reactivity against an antigen of interest may comprise a very  
530 small frequency of the total ASC compartment and are likely to possess a wider spectrum of  
531 affinity following *in vitro* polyclonal stimulation since these methods promote B cell  
532 differentiation independent of BCR encoded specificity. Therefore, it is imperative to introduce  
533 the appropriate negative controls into assays aiming at revealing underlying memory B cell  
534 reactivity, especially those bearing an unswitched IgM<sup>+</sup> BCR, following *in vitro* differentiation  
535 of donor PBMC [92]. Furthermore, a B cell stimulation protocol such as anti-CD40 + IL-4 + IL-  
536 21 that mimic physiologic B cell stimulation through helper T cells, rather than reliance on



537 mitogens or TLR agonists, enables selective activation of memory B cells [36] and may offer a  
538 superior strategy for identifying antigen-specific IgM<sup>+</sup> memory B cells following resolution of  
539 viral infections such as COVID-19.

540 In closing, the affinity capture approach introduced in this communication opens the door  
541 to systematic assessment of underlying memory B cell reactivity against a wide array of antigens  
542 regardless of their conformation and amino acid composition using the ImmunoSpot platform.  
543 Such might be essential for understanding immunity to SARS-CoV-2. Our ongoing studies  
544 reveal that low serum antibody reactivity to SARS-CoV-2 poorly reflects on the abundance of  
545 SARS-CoV-2 antigen-specific memory B cells in subjects who recovered from infection, and  
546 that such memory B cells can be regularly detected in recovered subjects even if the serum  
547 antibody levels were too low to confirm prior exposure (Wolf *et al.*, manuscript in preparation).  
548 As recent reports indicate that antibody titers against the SARS-CoV-2 Spike protein may  
549 decline over the course of months [15, 22, 23, 93], we suggest that the relevant assessment of B  
550 cell immunity in the context of the ongoing global pandemic exists at the level of memory B  
551 cells that can convey immune protection by engaging in a rapid secondary antibody response.  
552 We further contend that ImmunoSpot offers a suitable platform for the detailed study of SARS-  
553 CoV-2 Spike-reactive memory B cells and suggest its overall utility for identifying protective  
554 immune signatures acquired either through natural infection or following prophylactic  
555 vaccination.

556

## 557 REFERENCES

- 558 1. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. The  
559 *Journal of Clinical Investigation*. **1970**;49(4):673-80.

- 560 2. Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. *European*  
561 *Journal of Immunology*. **1988**;18(2):313-6.
- 562 3. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al. Rapid  
563 and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection  
564 in Humans. *Journal of Virology*. **2012**;86(6):2911-8.
- 565 4. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of  
566 high-affinity human monoclonal antibodies against influenza virus. *Nature*.  
567 **2008**;453(7195):667-71.
- 568 5. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.  
569 Breadth of concomitant immune responses prior to patient recovery: a case report of non-  
570 severe COVID-19. *Nature Medicine*. **2020**;26(4):453-5.
- 571 6. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels.  
572 *Annual Review of Immunology*. **2005**;23(1):367-86.
- 573 7. Smith KGC, Light A, O'Reilly LA, Ang S-M, Strasser A, Tarlinton D. bcl-2 Transgene  
574 Expression Inhibits Apoptosis in the Germinal Center and Reveals Differences in the  
575 Selection of Memory B Cells and Bone Marrow Antibody-Forming Cells. *Journal of*  
576 *Experimental Medicine*. **2000**;191(3):475-84.
- 577 8. Phan TG, Paus D, Chan TD, Turner ML, Nutt SL, Basten A, et al. High affinity  
578 germinal center B cells are actively selected into the plasma cell compartment. *Journal of*  
579 *Experimental Medicine*. **2006**;203(11):2419-24.
- 580 9. Lightman SM, Utley A, Lee KP. Survival of Long-Lived Plasma Cells (LLPC): Piecing  
581 Together the Puzzle. *Frontiers in Immunology*. **2019**;10(965).
- 582 10. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. *Nature Reviews*  
583 *Immunology*. **2005**;5(3):230-42.
- 584 11. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma  
585 cell differentiation and survival. *Current Opinion in Immunology*. **2006**;18(3):265-70.
- 586 12. Davis CW, Jackson KJL, McCausland MM, Darce J, Chang C, Linderman SL, et al.  
587 Influenza vaccine-induced human bone marrow plasma cells decline within a year after  
588 vaccination. *Science*. **2020**;370(6513):237-41.

- 589 13. Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, et al.  
590 Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. *Cell*.  
591 **2019**;177(6):1566-82.e17.
- 592 14. Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, et al. Longitudinal  
593 analysis of acute and convalescent B cell responses in a human primary dengue serotype  
594 2 infection model. *EBioMedicine*. **2019**;41:465-78.
- 595 15. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal  
596 observation and decline of neutralizing antibody responses in the three months following  
597 SARS-CoV-2 infection in humans. *Nature Microbiology*. **2020**;5(12):1598-607.
- 598 16. Bu W, Hayes GM, Liu H, Gemmell L, Schmeling DO, Radecki P, et al. Kinetics of  
599 Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary  
600 Infection with EBV. *Clinical and Vaccine Immunology*. **2016**;23(4):363-9.
- 601 17. Shibamura M, Yoshikawa T, Yamada S, Inagaki T, Nguyen PHA, Fujii H, et al.  
602 Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies  
603 to the HCMV glycoprotein complexes. *Virology Journal*. **2020**;17(1):120.
- 604 18. Shimamura M, Mach M, Britt WJ. Human Cytomegalovirus Infection Elicits a  
605 Glycoprotein M (gM)/gN-Specific Virus-Neutralizing Antibody Response. *Journal of*  
606 *Virology*. **2006**;80(9):4591-600.
- 607 19. Tarlinton D, Radbruch A, Hiepe F, Dörner T. Plasma cell differentiation and survival.  
608 *Current Opinion in Immunology*. **2008**;20(2):162-9.
- 609 20. Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, et al. Durability  
610 of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional  
611 Analysis. *Clinical Infectious Diseases*. **2016**;62(9):1111-8.
- 612 21. Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R, et al. Heterogeneity and  
613 longevity of antibody memory to viruses and vaccines. *PLOS Biology*.  
614 **2018**;16(8):e2006601.
- 615 22. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and  
616 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine*.  
617 **2020**;26(8):1200-4.

- 618 23. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory  
619 to SARS-CoV-2 assessed for up to 8 months after infection. *Science*.  
620 **2021**;371(6529):eabf4063.
- 621 24. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against  
622 pathogens. *Nature Reviews Immunology*. **2020**;20(4):229-38.
- 623 25. Engels N, Wienands J. Memory control by the B cell antigen receptor. *Immunological*  
624 *Reviews*. **2018**;283(1):150-60.
- 625 26. Palm A-KE, Henry C. Remembrance of Things Past: Long-Term B Cell Memory After  
626 Infection and Vaccination. *Frontiers in Immunology*. **2019**;10(1787).
- 627 27. Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. Challenges and  
628 Opportunities for Consistent Classification of Human B Cell and Plasma Cell  
629 Populations. *Frontiers in Immunology*. **2019**;10(2458).
- 630 28. Boonyaratanakornkit J, Taylor JJ. Techniques to Study Antigen-Specific B Cell  
631 Responses. *Frontiers in Immunology*. **2019**;10(1694).
- 632 29. Whittle JRR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, et al. Flow  
633 Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed  
634 Antibodies from Multiple Ig Heavy-Chain Lineages. *Journal of Virology*.  
635 **2014**;88(8):4047-57.
- 636 30. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for  
637 identification of HIV gp140 binding memory B cells in human blood. *Journal of*  
638 *Immunological Methods*. **2009**;343(2):65-7.
- 639 31. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al.  
640 Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*.  
641 **2021**;184(1):169-83.e17.
- 642 32. Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid  
643 generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in  
644 COVID-19 and convalescence. *Science Immunology*. **2020**;5(54):eabf8891.
- 645 33. Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, et al. High  
646 Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell*.  
647 **2019**;179(7):1636-46.e15.

- 648 34. Kwong PD, DeKosky BJ, Ulmer JB. Antibody-guided structure-based vaccines.  
649 *Seminars in Immunology*. **2020**;50:101428.
- 650 35. Finn JA, Dong J, Sevy AM, Parrish E, Gilchuk I, Nargi R, et al. Identification of  
651 Structurally Related Antibodies in Antibody Sequence Databases Using Rosetta-Derived  
652 Position-Specific Scoring. *Structure*. **2020**;28(10):1124-30.e5.
- 653 36. Franke F, Kirchenbaum GA, Kuerten S, Lehmann PV. IL-21 in Conjunction with Anti-  
654 CD40 and IL-4 Constitutes a Potent Polyclonal B Cell Stimulator for Monitoring  
655 Antigen-Specific Memory B Cells. *Cells*. **2020**;9(2):433.
- 656 37. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B  
657 cells: a sensitive and generalized ELISPOT system. *Journal of Immunological Methods*.  
658 **2004**;286(1):111-22.
- 659 38. Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, et al. An optimized assay for  
660 the enumeration of antigen-specific memory B cells in different compartments of the  
661 human body. *Journal of Immunological Methods*. **2010**;358(1):56-65.
- 662 39. Pinna D, Corti D, Jarrossay D, Sallusto F, Lanzavecchia A. Clonal dissection of the  
663 human memory B-cell repertoire following infection and vaccination. *European Journal*  
664 *of Immunology*. **2009**;39(5):1260-70.
- 665 40. Walsh PN, Friedrich DP, Williams JA, Smith RJ, Stewart TL, Carter DK, et al.  
666 Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine  
667 induced memory responses in HIV vaccine trials. *Journal of Immunological Methods*.  
668 **2013**;394(1):84-93.
- 669 41. Jahnmatz M, Kesa G, Netterlid E, Buisman A-M, Thorstensson R, Ahlborg N.  
670 Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced  
671 B-cell responses. *Journal of Immunological Methods*. **2013**;391(1):50-9.
- 672 42. Muir L, McKay PF, Petrova VN, Klymenko OV, Kratochvil S, Pinder CL, et al.  
673 Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare  
674 peripheral memory B cell subset responses. *Wellcome Open Res*. **2017**;2:97.
- 675 43. Czerkinsky CC, Nilsson L-Å, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase  
676 enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-  
677 secreting cells. *Journal of Immunological Methods*. **1983**;65(1):109-21.

- 678 44. Sundararaman S, Karulin AY, Ansari T, BenHamouda N, Gottwein J, Laxmanan S, et al.  
679 High Reproducibility of ELISPOT Counts from Nine Different Laboratories. *Cells*.  
680 **2015**;4(1):21-39.
- 681 45. Carter MJ, Mitchell RM, Meyer Sauteur PM, Kelly DF, Trück J. The Antibody-Secreting  
682 Cell Response to Infection: Kinetics and Clinical Applications. *Frontiers in Immunology*.  
683 **2017**;8(630).
- 684 46. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, et al.  
685 Broadly cross-reactive antibodies dominate the human B cell response against 2009  
686 pandemic H1N1 influenza virus infection. *Journal of Experimental Medicine*.  
687 **2011**;208(1):181-93.
- 688 47. Ellebedy AH, Krammer F, Li G-M, Miller MS, Chiu C, Wrammert J, et al. Induction of  
689 broadly cross-reactive antibody responses to the influenza HA stem region following  
690 H5N1 vaccination in humans. *Proceedings of the National Academy of Sciences*.  
691 **2014**;111(36):13133-8.
- 692 48. Bhaumik SK, Priyamvada L, Kauffman RC, Lai L, Natrajan MS, Cho A, et al. Pre-  
693 Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-  
694 Infected Patient. *Viruses*. **2019**;11(1):19.
- 695 49. Verheul AM, Versteeg AA, Westerdal NAC, Van Dam GJ, Jansze M, Snippe H.  
696 Measurement of the humoral immune response against streptococcus pneumoniae type  
697 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology.  
698 *Journal of Immunological Methods*. **1990**;126(1):79-87.
- 699 50. Gaultier GN, McCready W, Ulanova M. The effect of pneumococcal immunization on  
700 total and antigen-specific B cells in patients with severe chronic kidney disease. *BMC*  
701 *Immunology*. **2019**;20(1):41.
- 702 51. Tian C, Chen Y, Liu Y, Wang S, Li Y, Wang G, et al. Use of ELISpot assay to study  
703 HBs-specific B cell responses in vaccinated and HBV infected humans. *Emerging*  
704 *Microbes & Infections*. **2018**;7(1):1-10.
- 705 52. Kuerten S, Pommerschein G, Barth SK, Hohmann C, Milles B, Sammer FW, et al.  
706 Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements  
707 of brain-reactive B cells in the blood. *Clinical Immunology*. **2014**;152(1):20-4.

- 708 53. Taddeo A, Khodadadi L, Voigt C, Mumtaz IM, Cheng Q, Moser K, et al. Long-lived  
709 plasma cells are early and constantly generated in New Zealand Black/New Zealand  
710 White F1 mice and their therapeutic depletion requires a combined targeting of  
711 autoreactive plasma cells and their precursors. *Arthritis Research & Therapy*.  
712 **2015**;17(1):39.
- 713 54. Wang W, Rangel-Moreno J, Owen T, Barnard J, Nevarez S, Ichikawa HT, et al. Long-  
714 Term B Cell Depletion in Murine Lupus Eliminates Autoantibody-Secreting Cells and Is  
715 Associated with Alterations in the Kidney Plasma Cell Niche. *The Journal of*  
716 *Immunology*. **2014**;192(7):3011-20.
- 717 55. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, et al. Limited  
718 efficacy of inactivated influenza vaccine in elderly individuals is associated with  
719 decreased production of vaccine-specific antibodies. *The Journal of Clinical*  
720 *Investigation*. **2011**;121(8):3109-19.
- 721 56. Painter SD, Haralambieva IH, Ovsyannikova IG, Grill DE, Poland GA. Detection of  
722 Influenza A/H1N1-Specific Human IgG-Secreting B Cells in Older Adults by ELISPOT  
723 Assay. *Viral Immunology*. **2014**;27(2):32-8.
- 724 57. Caspell R, Lehmann PV. Detecting all Immunoglobulin Classes and Subclasses in a  
725 Multiplex 7 Color ImmunoSpot® Assay. In: Kalyuzhny AE, editor. *Handbook of*  
726 *ELISPOT : Methods and Protocols*. New York, NY: Springer New York; **2018**. p. 85-94.
- 727 58. Megyesi Z, Lehmann PV, Karulin AY. Multi-Color FLUOROSPOT Counting Using  
728 ImmunoSpot® Fluoro-X™ Suite. In: Kalyuzhny AE, editor. *Handbook of ELISPOT :*  
729 *Methods and Protocols*. New York, NY: Springer New York; **2018**. p. 115-31.
- 730 59. Karulin AY, Lehmann PV. How ELISPOT Morphology Reflects on the Productivity and  
731 Kinetics of Cells' Secretary Activity. In: Kalyuzhny AE, editor. *Handbook of ELISPOT:*  
732 *Methods and Protocols*. Totowa, NJ: Humana Press; **2012**. p. 125-43.
- 733 60. Priyamvada L, Cho A, Onlamoon N, Zheng N-Y, Huang M, Kovalenkov Y, et al. B Cell  
734 Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-  
735 Reactive, Memory-Derived Plasmablasts. *Journal of Virology*. **2016**;90(12):5574-85.
- 736 61. Kirchenbaum GA, Allen JD, Layman TS, Sautto GA, Ross TM. Infection of Ferrets with  
737 Influenza Virus Elicits a Light Chain–Biased Antibody Response against Hemagglutinin.  
738 *The Journal of Immunology*. **2017**;199(11):3798-807.

- 739 62. Bromage E, Stephens R, Hassoun L. The third dimension of ELISPOTs: Quantifying  
740 antibody secretion from individual plasma cells. *Journal of Immunological Methods*.  
741 **2009**;346(1):75-9.
- 742 63. Kalyuzhny AE. Membrane Microplates for One- and Two-Color ELISPOT and  
743 FLUOROSPOT Assays. In: Kurien BT, Scofield RH, editors. *Western Blotting: Methods*  
744 *and Protocols*. New York, NY: Springer New York; **2015**. p. 435-47.
- 745 64. Weiss AJ. Overview of Membranes and Membrane Plates Used in Research and  
746 Diagnostic ELISPOT Assays. In: Kalyuzhny AE, editor. *Handbook of ELISPOT:*  
747 *Methods and Protocols*. Totowa, NJ: Humana Press; **2012**. p. 243-56.
- 748 65. Ramachandran H, Laux J, Moldovan I, Caspell R, Lehmann PV, Subbramanian RA.  
749 Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in  
750 High-Throughput Human Immune Monitoring Studies. *Cells*. **2012**;1(3):313-24.
- 751 66. Fecher P, Caspell R, Naeem V, Karulin AY, Kuerten S, Lehmann PV. B Cells and B Cell  
752 Blasts Withstand Cryopreservation While Retaining Their Functionality for Producing  
753 Antibody. *Cells*. **2018**;7(6):50.
- 754 67. Ecker JW, Kirchenbaum GA, Pierce SR, Skarlupka AL, Abreu RB, Cooper RE, et al.  
755 High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from  
756 Stably-Transfected Mammalian Cell Lines. *Vaccines*. **2020**;8(3):462.
- 757 68. Hsieh C-L, Goldsmith JA, Schaub JM, DiVenere AM, Kuo H-C, Javanmardi K, et al.  
758 Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*.  
759 **2020**;369(6510):1501-5.
- 760 69. The following reagent was produced under HHSN272201400008C and obtained through  
761 BEI Resources N, NIH: Vector pCAGGS Containing the SARS-Related Coronavirus 2,  
762 Wuhan-Hu-1 Spike Glycoprotein Receptor Binding Domain (RBD), NR-52309.
- 763 70. Sautto GA, Kirchenbaum GA, Abreu RB, Ecker JW, Pierce SR, Kleanthous H, et al. A  
764 Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza  
765 Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against  
766 Hemagglutinin. *The Journal of Immunology*. **2020**;204(2):375-85.
- 767 71. The following reagent was deposited by the Centers for Disease Control and Prevention  
768 and obtained through BEI Resources N, NIH: SARS-Related Coronavirus 2, Isolate  
769 USA-WA1/2020, Heat Inactivated, NR-52286.



- 770 72. Kirchenbaum GA, Ross TM. Generation of Monoclonal Antibodies against  
771 Immunoglobulin Proteins of the Domestic Ferret *Mustela putorius furo*. *Journal of*  
772 *Immunology Research*. **2017**;2017:5874572.
- 773 73. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson J-P, et al.  
774 Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal  
775 Betacoronaviruses. *Journal of Clinical Immunology*. **2021**.  
776 <https://doi.org/10.1007/s10875-021-00997-6>
- 777 74. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et  
778 al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. *Cell*  
779 *Reports Medicine*. **2020**;1(3):100040.
- 780 75. Mantus G, Nyhoff LE, Kauffman RC, Edara VV, Lai L, Floyd K, et al. Evaluation of  
781 Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the  
782 Functional Importance of the Receptor-Binding Domain. *The Journal of Immunology*.  
783 **2021**;ji2001420.
- 784 76. Dunmire SK, Hogquist KA, Balfour HH. Infectious Mononucleosis. In: Münz C, editor.  
785 *Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases*. Cham: Springer  
786 International Publishing; **2015**. p. 211-40.
- 787 77. Kempkes B, Robertson ES. Epstein-Barr virus latency: current and future perspectives.  
788 *Current Opinion in Virology*. **2015**;14:138-44.
- 789 78. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV Persistence Involves Strict  
790 Selection of Latently Infected B Cells. *The Journal of Immunology*. **2000**;165(6):2975
- 791 79. Frappier L. The Epstein-Barr Virus EBNA1 Protein. *Scientifica*. **2012**;2012:438204.
- 792 80. Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz CA, et al. Antibody  
793 responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in  
794 acute and chronic Epstein-Barr virus infection. *Proceedings of the National Academy of*  
795 *Sciences*. **1987**;84(2):570-4.
- 796 81. Ha S, Li F, Troutman MC, Freed DC, Tang A, Loughney JW, et al. Neutralization of  
797 Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral  
798 gH/gL/pUL128-131 Pentameric Complex. *Journal of Virology*. **2017**;91(7):e02033-16.
- 799 82. Bornhorst JA, Falke JJ. Purification of proteins using polyhistidine affinity tags. *Methods*  
800 *in Enzymology*. 326: Academic Press; **2000**. p. 245-54.

- 801 83. Zhao X, Li G, Liang S. Several affinity tags commonly used in chromatographic  
802 purification. *J Anal Methods Chem.* **2013**;2013:581093-.
- 803 84. Einhauer A, Jungbauer A. The FLAG™ peptide, a versatile fusion tag for the purification  
804 of recombinant proteins. *Journal of Biochemical and Biophysical Methods.*  
805 **2001**;49(1):455-65.
- 806 85. Moon J-M, Kim G-Y, Rhim H. A new idea for simple and rapid monitoring of gene  
807 expression: requirement of nucleotide sequences encoding an N-terminal HA tag in the  
808 T7 promoter-driven expression in *E. coli*. *Biotechnology Letters.* **2012**;34(10):1841-6.
- 809 86. Hillman MC, Yang LS, Sun S, Duke JL, O'Neil KT, Kochie JE, et al. A Comprehensive  
810 System for Protein Purification and Biochemical Analysis Based on Antibodies to c-myc  
811 Peptide. *Protein Expression and Purification.* **2001**;23(2):359-68.
- 812 87. Schmidt TGM, Koepke J, Frank R, Skerra A. Molecular Interaction Between the Strep-  
813 tag Affinity Peptide and its Cognate Target, Streptavidin. *Journal of Molecular Biology.*  
814 **1996**;255(5):753-66.
- 815 88. Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, et al. Impact of  
816 age and pre-existing influenza immune responses in humans receiving split inactivated  
817 influenza vaccine on the induction of the breadth of antibodies to influenza A strains.  
818 *PLOS ONE.* **2017**;12(11):e0185666.
- 819 89. McCarthy KR, Raymond DD, Do KT, Schmidt AG, Harrison SC. Affinity maturation in  
820 a human humoral response to influenza hemagglutinin. *Proceedings of the National*  
821 *Academy of Sciences.* **2019**;116(52):26745-51.
- 822 90. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quataert SA, et al. Frequencies of  
823 human influenza-specific antibody secreting cells or plasmablasts post vaccination from  
824 fresh and frozen peripheral blood mononuclear cells. *Journal of Immunological*  
825 *Methods.* **2009**;340(1):42-7.
- 826 91. Varnaitė R, García M, Glans H, Maleki KT, Sandberg JT, Tynell J, et al. Expansion of  
827 SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing  
828 Antibodies in Hospitalized COVID-19 Patients. *The Journal of Immunology.*  
829 **2020**;205(9):2437-46.

- 830 92. Ansari A, Arya R, Sachan S, Jha SN, Kalia A, Lall A, et al. Immune Memory in Mild  
831 COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After  
832 SARS- CoV-2 Infection. *Frontiers in Immunology*. **2021**;12(749).
- 833 93. Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, et al.  
834 Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID  
835 19 exposure. *JCI Insight*. **2021**;6(9).
- 836

837 **Main Text Figure Legends**

838 **Figure 1: Affinity tag capture improves detection of SARS-CoV-2 RBD-reactive ASC.**

839 PBMC from four PCR-confirmed COVID-19 donors were *in vitro* stimulated (detailed in  
840 Materials and Methods) and evaluated for antibody-secreting (ASC) reactivity against the  
841 receptor binding domain (RBD) fragment of the SARS-CoV-2 Spike protein. A) Representative  
842 wells images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10µg/mL of  
843 RBD protein or through affinity capture using the genetically encoded hexahistidine (6XHis) tag.  
844 Magnification and contrast enhancements were uniformly performed on all images to aid their  
845 visualization in publication. B) RBD-specific FluoroSpots were merged into flow cytometry  
846 standard (FCS) files (detailed in Materials and Methods) and visualized as bivariate plots  
847 measuring spot intensity (x-axis) and spot size (y-axis). FluoroSpots originating from assay wells  
848 in which RBD protein was directly captured on the membrane (black dots) or through affinity  
849 capture (red) are shown as overlays. The combined number of FluoroSpots (spot forming units,  
850 SFU) detected in replicate wells for each of the respective donors is indicated in the inset using  
851 the same red/black color code.

852

853 **Figure 2: Affinity tag capture improves detection of SARS-CoV-2 S1-reactive ASC.** PBMC

854 from four PCR-confirmed COVID-19 donors were *in vitro* stimulated and evaluated for  
855 antibody-secreting (ASC) reactivity against the S1 subunit of the SARS-CoV-2 Spike protein. A)  
856 Representative wells images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with  
857 10µg/mL of S1 protein or through affinity capture using the genetically encoded hexahistidine  
858 (6XHis) tag. Magnification and contrast enhancements were uniformly performed on all images  
859 to aid their visualization in publication. B) S1-specific FluoroSpots were merged into FCS files

860 and visualized as bivariate plots. FluoroSpots originating from assay wells in which S1 protein  
861 was directly captured on the membrane (black dots) or through affinity capture (red) are shown  
862 as overlays. The combined number of FluoroSpots detected in replicate wells for each of the  
863 respective donors is indicated in the inset using the same red/black color code.

864

865 **Figure 3: Detection of SARS-CoV-2 Spike-specific FluoroSpots is influenced by protein**  
866 **coating efficiency.** Murine B cell hybridomas (~100 cells/well) were evaluated for total or  
867 antigen-specific FluoroSpot formation (detailed in Materials and Methods). A) Representative  
868 well images of murine B cell hybridomas secreting monoclonal antibody (mAb) (IgG1,  $\kappa$ ) with  
869 specificity for the full-length (FL) SARS-CoV-2 Spike protein. Contrast enhancements were  
870 uniformly performed on all images to aid their visualization in publication. B) Total or Spike-  
871 specific SFU/well (mean  $\pm$  SD) for each B cell hybridoma line. Significant differences in  
872 SFU/well were determined using an analysis of variation (ANOVA) with Sidak's post-hoc test.  
873 \*\*\* $p < 0.001$ . C) Spike-specific FluoroSpots were merged into FCS files and visualized as  
874 bivariate plots. FluoroSpots originating from assay wells in which Spike protein was directly  
875 captured on the membrane (black dots) or through affinity capture (red) are shown as overlays.  
876 The combined number of FluoroSpots detected in replicate wells for each of the respective  
877 donors is indicated in the inset using the same red/black color code.

878

879 **Figure 4: Improved sensitivity of EBNA1-specific ASC through affinity capture of coating**  
880 **antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC) reactivity  
881 against the Epstein-Barr nuclear antigen 1 (EBNA1) protein from EBV. A) Representative wells

882 images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10µg/mL of EBNA1  
883 protein or through affinity capture using the genetically encoded hexahistidine (6XHis) tag.  
884 Magnification and contrast enhancements were uniformly performed on all images to aid their  
885 visualization in publication. B) EBNA1-specific FluoroSpots were merged into FCS files and  
886 visualized as bivariate plots. FluoroSpots originating from assay wells in which EBNA1 protein  
887 was directly captured on the membrane (black dots) or through affinity capture (red) are shown  
888 as overlays. The combined number of FluoroSpots detected in replicate wells for each of the  
889 respective donors is indicated in the inset using the same red/black color code.

890

891 **Figure 5: Improved sensitivity of gH-specific ASC through affinity capture of coating**  
892 **antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC) reactivity  
893 against the gH pentamer complex protein from HCMV. A) Representative wells images  
894 depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10µg/mL of gH pentamer  
895 complex protein, or through affinity capture using the genetically encoded hexahistidine (6XHis)  
896 tag. Magnification and contrast enhancements were uniformly performed on all images to aid  
897 their visualization in publication. B) gH-specific FluoroSpots were merged into FCS files and  
898 visualized as bivariate plots. FluoroSpots originating from assay wells in which gH pentamer  
899 complex was directly captured on the membrane (black dots) or through affinity capture (red) are  
900 shown as overlays. The combined number of FluoroSpots detected in replicate wells for each of  
901 the respective donors is indicated in the inset using the same red/black color code.

902

903 **Figure 6: Improved sensitivity of CA/09 rHA-specific ASC through affinity capture of**  
904 **coating antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC)  
905 reactivity against recombinant hemagglutinin protein representing the A/California/04/2009  
906 (CA/09) H1N1 vaccine strain. A) Representative wells images depicting antigen-specific IgG<sup>+</sup>  
907 ASC in wells coated directly with 10µg/mL of CA/09 rHA or through affinity capture using the  
908 genetically encoded hexahistidine (6XHis) tag. Magnification and contrast enhancements were  
909 uniformly performed on all images to aid their visualization in publication. B) CA/09 rHA-  
910 specific FluoroSpots were merged into FCS files and visualized as bivariate plots. FluoroSpots  
911 originating from assay wells in which CA/09 rHA was directly captured on the membrane (black  
912 dots) or through affinity capture (red) are shown as overlays. The combined number of  
913 FluoroSpots detected in replicate wells for each of the respective donors is indicated in the inset  
914 using the same red/black color code.

915

916 **Figure 7: Detection of CA/09 rHA-specific FluoroSpots is influenced by protein coating**  
917 **efficiency.** Murine B cell hybridomas (~100 cells/well) were evaluated for total or antigen-  
918 specific FluoroSpot formation. A) Representative well images of murine B cell hybridomas  
919 secreting monoclonal antibody (mAb) (IgG1, κ) with specificity for the recombinant  
920 hemagglutinin protein representing the A/California/04/2009 (CA/09) H1N1 vaccine strain.  
921 Contrast enhancements were uniformly performed on all images to aid their visualization in  
922 publication. B) Total or CA/09 rHA-specific SFU/well (mean ± SD) for each B cell hybridoma  
923 line. Significant differences in SFU/well were determined using an analysis of variation  
924 (ANOVA) with Sidak's post-hoc test. \*\*\*p<0.001. C) CA/09 rHA-specific FluoroSpots were  
925 merged into FCS files and visualized as bivariate plots. FluoroSpots originating from assay wells

926 in which CA/09 rHA was directly captured on the membrane (black dots) or through affinity  
927 capture (red) are shown as overlays. The combined number of FluoroSpots detected in replicate  
928 wells for each of the respective donors is indicated in the inset using the same red/black color  
929 code.

930



931 **ACKNOWLEDGEMENTS**

932 We thank Magdalena Tary-Lehmann for valuable suggestions and comments on the  
933 manuscript. Additionally, we thank Jeffrey Ecker and Spencer Pierce of the Center for Vaccines  
934 and Immunology (CVI) for expression and purification of recombinant proteins. We also thank  
935 Tibor Baki and Victoria Gaidaenko from CTL, and Melisa Sebok, Malachi Wickman and  
936 Jennifer Penfold from American Red Cross for their help in acquiring PBMC from convalescent  
937 COVID-19 donors. This research was performed in fulfillment of the requirements for obtaining  
938 the degree “Dr. med. dent.” by Sebastian Köppert at Friedrich-Alexander University Erlangen-  
939 Nürnberg (FAU), Germany.

940

941 **Author Contributions:** Conceptualization, S.K., F.F., P.V.L. and G.A.K.; Methodology, S.K.,  
942 C.W., N.B., F.F. and G.A.K; Formal Analysis, S.K., C.W., N.B. and G.A.K; Investigation, S.K.,  
943 C.W., F.F., N.B. and G.A.K.; Resources, G.A.S. and T.M.R.; Data Curation, S.K., C.W., N.B. and  
944 G.A.K; Writing – Original Draft Preparation, S.K. and G.A.K.; Writing – Review & Editing. C.W.  
945 N.B., F.F., G.A.S., S.K., T.M.R. and P.V.L.; Supervision, P.V.L. and G.A.K; Project  
946 Administration, G.A.K. All authors have read and agreed to the published version of the  
947 manuscript.

948

949 **Funding:** This study, with the exception of the murine B cell hybridomas secreting mAb against  
950 the SARS-CoV-2 Spike protein (UGA001), was funded by the Research and Development budget  
951 of Cellular Technology Limited.

952

953 **Institutional Review Board Statement:** PBMC used in this study were collected from Hemacare  
954 (Van Nuys, CA) (Biorepository Protocol 001, approved by external Advarra IRB) or American  
955 Red Cross (Atlanta, GA) (Protocol Number 2016-030, approved by internal IRB) and donors  
956 provided consent to usage of material for research purposes. Cell material was sold to CTL  
957 identifying donors by code only. Mouse immunizations were conducted in accordance with an  
958 IACUC approved protocol (A2020 02-024-Y2-A5, approved 4/1/2020) at the University of  
959 Georgia.

960

961 **Data Availability Statement:** The data generated in this study will be made available by the  
962 authors, without undue reservation, to any qualified research.


963

964 **Conflicts of Interest:** P.V.L is Founder, President and CEO of CTL, a company that specializes  
965 in immune monitoring by ELISPOT testing, producing high-throughput-suitable readers, test kits,  
966 and GLP-compliant contract research. G.A.K and N.B. are also employees of CTL. The mouse  
967 anti-SARS-CoV-2 Spike mAbs, developed by G.A.S. and T.M.R, have been filed with the  
968 Innovation Gateway at the University of Georgia and are currently licenses for distribution by  
969 Kerast. S.K., C.W., F.F. and S.K. declare no conflict of interest.

970

971 **Figure 1:**

972



973

974

975 **Figure 1: Affinity tag capture improves detection of SARS-CoV-2 RBD-reactive ASC.**


976 PBMC from four PCR-confirmed COVID-19 donors were *in vitro* stimulated (detailed in  
977 Materials and Methods) and evaluated for antibody-secreting (ASC) reactivity against the  
978 receptor binding domain (RBD) fragment of the SARS-CoV-2 Spike protein. A) Representative  
979 wells images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10µg/mL of  
980 RBD protein or through affinity capture using the genetically encoded hexahistidine (6XHis) tag.  
981 Magnification and contrast enhancements were uniformly performed on all images to aid their  
982 visualization in publication. B) RBD-specific FluoroSpots were merged into flow cytometry  
983 standard (FCS) files (detailed in Materials and Methods) and visualized as bivariate plots  
984 measuring spot intensity (x-axis) and spot size (y-axis). FluoroSpots originating from assay wells  
985 in which RBD protein was directly captured on the membrane (black dots) or through affinity  
986 capture (red) are shown as overlays. The combined number of FluoroSpots (spot forming units,  
987 SFU) detected in replicate wells for each of the respective donors is indicated in the inset using  
988 the same red/black color code.

989

990

991 **Figure 2:**

992



993

994

995


996 **Figure 2: Affinity tag capture improves detection of SARS-CoV-2 S1-reactive ASC.** PBMC  
997 from four PCR-confirmed COVID-19 donors were *in vitro* stimulated and evaluated for  
998 antibody-secreting (ASC) reactivity against the S1 subunit of the SARS-CoV-2 Spike protein. A)  
999 Representative wells images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with  
1000 10µg/mL of S1 protein or through affinity capture using the genetically encoded hexahistidine  
1001 (6XHis) tag. Magnification and contrast enhancements were uniformly performed on all images  
1002 to aid their visualization in publication. B) S1-specific FluoroSpots were merged into FCS files  
1003 and visualized as bivariate plots. FluoroSpots originating from assay wells in which S1 protein  
1004 was directly captured on the membrane (black dots) or through affinity capture (red) are shown  
1005 as overlays. The combined number of FluoroSpots detected in replicate wells for each of the  
1006 respective donors is indicated in the inset using the same red/black color code.

1007

1008

1009 **Figure 3:**

1010



1011

1012

1013

1014

1015 **Figure 3: Detection of SARS-CoV-2 Spike-specific FluoroSpots is influenced by protein**  
 1016 **coating efficiency.** Murine B cell hybridomas (~100 cells/well) were evaluated for total or  
 1017 antigen-specific FluoroSpot formation (detailed in Materials and Methods). A) Representative  
 1018 well images of murine B cell hybridomas secreting monoclonal antibody (mAb) (IgG1,  $\kappa$ ) with  
 1019 specificity for the full-length (FL) SARS-CoV-2 Spike protein. Contrast enhancements were  
 1020 uniformly performed on all images to aid their visualization in publication. B) Total or Spike-  
 1021 specific SFU/well (mean  $\pm$  SD) for each B cell hybridoma line. Significant differences in  
 1022 SFU/well were determined using an analysis of variation (ANOVA) with Sidak's post-hoc test.  
 1023 \*\*\*p<0.001. C) Spike-specific FluoroSpots were merged into FCS files and visualized as  
 1024 bivariate plots. FluoroSpots originating from assay wells in which Spike protein was directly  
 1025 captured on the membrane (black dots) or through affinity capture (red) are shown as overlays.  
 1026 The combined number of FluoroSpots detected in replicate wells for each of the respective  
 1027 donors is indicated in the inset using the same red/black color code.


1028

1029

1030

1031 **Figure 4:**

1032



1033

1034

1035

1036 **Figure 4: Improved sensitivity of EBNA1-specific ASC through affinity capture of coating**  
1037 **antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC) reactivity  
1038 against the Epstein-Barr nuclear antigen 1 (EBNA1) protein from EBV. A) Representative wells  
1039 images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10µg/mL of EBNA1  
1040 protein or through affinity capture using the genetically encoded hexahistidine (6XHis) tag.  
1041 Magnification and contrast enhancements were uniformly performed on all images to aid their  
1042 visualization in publication. B) EBNA1-specific FluoroSpots were merged into FCS files and  
1043 visualized as bivariate plots. FluoroSpots originating from assay wells in which EBNA1 protein  
1044 was directly captured on the membrane (black dots) or through affinity capture (red) are shown  
1045 as overlays. The combined number of FluoroSpots detected in replicate wells for each of the  
1046 respective donors is indicated in the inset using the same red/black color code.

1047

1048


1049

1050

1051 **Figure 5:**

1052

1053



1054

1055

1056

1057 **Figure 5: Improved sensitivity of gH-specific ASC through affinity capture of coating**  
1058 **antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC) reactivity  
1059 against the gH pentamer complex protein from HCMV. A) Representative wells images  
1060 depicting antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10 $\mu$ g/mL of gH pentamer  
1061 complex protein, or through affinity capture using the genetically encoded hexahistidine (6XHis)  
1062 tag. Magnification and contrast enhancements were uniformly performed on all images to aid  
1063 their visualization in publication. B) gH-specific FluoroSpots were merged into FCS files and  
1064 visualized as bivariate plots. FluoroSpots originating from assay wells in which gH pentamer  
1065 complex was directly captured on the membrane (black dots) or through affinity capture (red) are  
1066 shown as overlays. The combined number of FluoroSpots detected in replicate wells for each of  
1067 the respective donors is indicated in the inset using the same red/black color code.

1068


1069

1070

1071 **Figure 6:**

1072

1073



1074

1075

1076

1077 **Figure 6: Improved sensitivity of CA/09 rHA-specific ASC through affinity capture of**  
1078 **coating antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC)  
1079 reactivity against recombinant hemagglutinin protein representing the A/California/04/2009  
1080 (CA/09) H1N1 vaccine strain. A) Representative wells images depicting antigen-specific IgG<sup>+</sup>  
1081 ASC in wells coated directly with 10µg/mL of CA/09 rHA or through affinity capture using the  
1082 genetically encoded hexahistidine (6XHis) tag. Magnification and contrast enhancements were  
1083 uniformly performed on all images to aid their visualization in publication. B) CA/09 rHA-  
1084 specific FluoroSpots were merged into FCS files and visualized as bivariate plots. FluoroSpots  
1085 originating from assay wells in which CA/09 rHA was directly captured on the membrane (black  
1086 dots) or through affinity capture (red) are shown as overlays. The combined number of  
1087 FluoroSpots detected in replicate wells for each of the respective donors is indicated in the inset  
1088 using the same red/black color code.

1089


1090

1091



1092 **Figure 7:**

1093



1094

1095

1096

1097


1098 **Figure 7: Detection of CA/09 rHA-specific FluoroSpots is influenced by protein coating**  
 1099 **efficiency.** Murine B cell hybridomas (~100 cells/well) were evaluated for total or antigen-  
 1100 specific FluoroSpot formation. A) Representative well images of murine B cell hybridomas  
 1101 secreting monoclonal antibody (mAb) (IgG1, κ) with specificity for the recombinant  
 1102 hemagglutinin protein representing the A/California/04/2009 (CA/09) H1N1 vaccine strain.  
 1103 Contrast enhancements were uniformly performed on all images to aid their visualization in  
 1104 publication. B) Total or CA/09 rHA-specific SFU/well (mean ± SD) for each B cell hybridoma  
 1105 line. Significant differences in SFU/well were determined using an analysis of variation  
 1106 (ANOVA) with Sidak's post-hoc test. \*\*\*p<0.001. C) CA/09 rHA-specific FluoroSpots were  
 1107 merged into FCS files and visualized as bivariate plots. FluoroSpots originating from assay wells  
 1108 in which CA/09 rHA was directly captured on the membrane (black dots) or through affinity  
 1109 capture (red) are shown as overlays. The combined number of FluoroSpots detected in replicate  
 1110 wells for each of the respective donors is indicated in the inset using the same red/black color  
 1111 code.

1112

1113

1114

1115 **Figure S1:**



1116


1117

1118 **Supplementary Figure 1: Improved detection of gH-specific ASC through affinity capture**  
1119 **of coating antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-secreting (ASC)  
1120 reactivity against the gH pentamer complex protein from HCMV. A) Representative wells  
1121 images depicting antigen-specific IgG<sup>+</sup> ASC in wells coated through affinity capture using the  
1122 genetically encoded hexahistidine (6XHis) tag. Magnification and contrast enhancements were  
1123 uniformly performed on all images to aid their visualization in publication. B) gH-specific  
1124 FluoroSpots were merged into FCS files and visualized as bivariate plots. FluoroSpots  
1125 originating from assay wells in which the gH pentamer complex was coated at 10µg/mL (red) or  
1126 20µg/mL (blue) are shown as overlays. The combined number of FluoroSpots detected in  
1127 replicate wells for each of the respective donors is indicated in the inset using the same red/blue  
1128 color code.

1129

1130 **Figure S2:**

1131



1132

1133

1134 **Supplementary Figure 2: Improved sensitivity of TX/12 rHA-specific ASC through affinity**

1135 **capture of coating antigen.** PBMC were *in vitro* stimulated and evaluated for antibody-

1136 secreting (ASC) reactivity against recombinant hemagglutinin protein representing the

1137 A/Texas/50/2012 (TX/12) H3N2 vaccine strain. A) Representative wells images depicting

1138 antigen-specific IgG<sup>+</sup> ASC in wells coated directly with 10μg/mL of TX/12 rHA or through

1139 affinity capture using the genetically encoded hexahistidine (6XHis) tag. Magnification and

1140 contrast enhancements were uniformly performed on all images to aid their visualization in

1141 publication. B) TX/12 rHA-specific FluoroSpots were merged into FCS files and visualized as

1142 bivariate plots. FluoroSpots originating from assay wells in which TX/12 rHA was directly

1143 captured on the membrane (black dots) or through affinity capture (red) are shown as overlays.

1144 The combined number of FluoroSpots detected in replicate wells for each of the respective

1145 donors is indicated in the inset using the same red/black color code.

1146

1147

1148